| scholarly article | Q13442814 |
| P2093 | author name string | Gail Torkildsen | |
| Mike Taylor | |||
| Ajay Duggal | |||
| John D Sheppard | |||
| Matthew C T Fyfe | |||
| George Ousler | |||
| Steve Webber | |||
| Adele Rowley | |||
| Claire Walshe | |||
| P2860 | cites work | Putting vital stains in context. | Q50489431 |
| Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. | Q50888488 | ||
| Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. | Q50933029 | ||
| Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. | Q54117205 | ||
| Reliability and validity of the Ocular Surface Disease Index | Q73801624 | ||
| Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review | Q26770830 | ||
| Safety and efficacy of cyclosporine in the treatment of chronic dry eye. | Q33825538 | ||
| Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells | Q34472557 | ||
| Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence | Q35570541 | ||
| Aqueous Tear Deficiency Increases Conjunctival Interferon-γ (IFN-γ) Expression and Goblet Cell Loss | Q36345503 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining | Q37052597 | ||
| An update on dry eye disease molecular treatment: advances in drug pipelines | Q38207723 | ||
| Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older | Q38680274 | ||
| Report of the Inaugural Meeting of the TFOS i(2) = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment | Q38699053 | ||
| Hot Topics in Dry Eye Disease. | Q39032670 | ||
| Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease | Q39069560 | ||
| Dry eye disease in an adult population in South-West Nigeria | Q39616989 | ||
| Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. | Q41316622 | ||
| Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis | Q41826640 | ||
| Validation and verification of the OPI 2.0 System | Q41839224 | ||
| The Relationship between Habitual Patient-Reported Symptoms and Clinical Signs among Patients with Dry Eye of Varying Severity | Q44631963 | ||
| Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye. | Q47098857 | ||
| Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review | Q47100458 | ||
| Key questions in a dry eye history. | Q49010135 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| placebo | Q269829 | ||
| Ded | Q30601669 | ||
| P304 | page(s) | 261-275 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease | |
| P478 | volume | 13 |
Search more.